Validation of Therapeutic Efficacy Targeting the Splicing Variants in Cystic Fibrosis and CFTR Pathologies (ONB-CFTR)

Cystic Fibrosis, an inherited autosomal recessive disease, arises from mutations in the CFTR gene. For intronic mutations affecting splicing events, oligonucleotides therapy has the potential to restore the production of the full length CFTR protein. Recent scientific research has demonstrated the potential of this approach to restore full length mRNA CFTR in in vitro human airway cells. The study aims to validate the therapeutic efficacy of oligonucleotide blockers (ONB) that target splicing defects associated to splicing variants in epithelia obtained from patients with Cystic Fibrosis and CFTR-related disorders.

Study Overview

• Status: Recruiting
• Conditions: Cystic Fibrosis; CFTR Gene Mutation
• Intervention / Treatment: Procedure: Nasal cells sampling; Procedure: Rectal biopsy sampling

Detailed Description

The study will include patients with various CFTR genotypes. The assessment of ONB (named ONB-CFTR) will be performed using an air-liquid interface model of airway epithelium, developed from nasal cells of patients, without or with a combination of existing CFTR modulators, depending on the patient' genotype.

This study will also aim to build a local biobank of rectal organoids from patients (only from Montpellier, France) carrying rare CFTR disease-causing variants.

• Study Type: Interventional
• Enrollment (Estimated): 20
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Anne Bergougnoux, PhD, PharmD; Phone Number: +33 411759879; Email: anne.bergougnoux@inserm.fr
• Study Contact Backup: Name: Magali Taulan-Cadars, PhD; Phone Number: +33 411759846; Email: magali.taulan@inserm.fr

Study Locations

• France
  • Montpellier, France, 34090
    • Recruiting
    • Montpellier University Hospital
    • Contact: Anne Bergougnoux, phD, PharmD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• The subject must have given their free and informed consent and signed the consent
• The subject must be affiliated or beneficiary of a health insurance plan Women and men are included
• The patient is at least 12 years old.
• The patient has cystic fibrosis or a CFTR pathology and therefore carries two mutations (with at least one mutation affecting splicing) in the CFTR gene.
• Patients who volunteer for rectal biopsy collection (only from Montpellier University Hospital) must be at least 18 years old.

Exclusion Criteria:

• The subject is in a period of exclusion determined by a previous study.
• The subject is under judicial protection, under guardianship or under curatorship
• The subject does not accept to sign consent
• It turns out to be impossible to give informed information to the subject
• The subject does not read the French language fluently
• The subject is a pregnant or breastfeeding woman
• The subject has porphyria, or has hepatic insufficiency, or suffers from epilepsy, or suffers from conduction disorders, or suffers from severe heart failure, has a cons-indication to the use of a local anesthetic spray.

Specific non-inclusion criteria for rectal sampling:

• the subject has thrombocytopenia
• the subject has a bleeding disorder
• The patient has severe inflammation of the rectum.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Nasal cells sampling and/or rectal biospy; Depending of the patient' genotype, specific ONB-CFTR (50 nM) will be incubated at the apical face of in vitro epithelium, alone and in combination with CFTR modulators. Efficacy of ONB will be compared to a condition with oligonucleotide control incubation. Rectal biopsies from volunteer patients were stored as a bio-bank of organoids.	Procedure: Nasal cells sampling; Nasal epithelium brushing in intermediate turbinate using a specific curette following a local anesthesia with Xylocaine 5% nebulizer.; Procedure: Rectal biopsy sampling; Forceps Biopsy Procedure (Servidoni et al., 2013) Only for volunteer patients included in the Montpellier center.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Restoration of the correctly spliced CFTR mRNA (full length) using specific ONB-CFTR (designed for one splicing variant).	The increase will be assessed in comparison to oligonucleotide-control effect by using semi-quantitative fluorescent PCR.	21 days after the air-liquid switch of epithelia (i.e. full differentiation)
Restoration of the mature CFTR protein using specific ONB-CFTR (designed for one splicing variant).	The increase will be assessed in comparison to oligonucleotide-control effect by using western blot	21 days after the air-liquid switch of epithelia (i.e. full differentiation)
Restoration of CFTR channel function using specific ONB-CFTR (designed for one splicing variant).	The increase will be assessed in comparison to oligonucleotide-control effect by using electrophysiological assays (Ussing chamber).	21 days after the air-liquid switch of epithelia (i.e. full differentiation)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Restoration of the correctly spliced CFTR mRNA (full length) and mature CFTR protein and CFTR channel function using a pool of ONB-CFTR (a mix of specific ONB-CFTR).	The increase will be assessed in comparison to oligonucleotide-control effect by using semi-quantitative fluorescent PCR, western blot and electrophysiological assays (Ussing chamber).	21 days after the air-liquid switch of epithelia (i.e. full differentiation)
Assessment of the amount of CFTR mRNA with normal splicing under the conditions tested.	That parameter will be quantified in comparison to oligonucleotide-control effect by using quantitative PCR assays.	21 days after the air-liquid switch of epithelia (i.e. full differentiation)
Assessment of the amount of mature CFTR proteins under the conditions tested.	That parameter will be quantified in comparison to oligonucleotide-control effect by using western blot assays.	21 days after the air-liquid switch of epithelia (i.e. full differentiation)
Assessment of the CFTR channel activity under the conditions tested.	That parameter will be quantified in comparison to oligonucleotide-control effect by using electrophysiological assays (Ussing chamber).	21 days after the air-liquid switch of epithelia (i.e. full differentiation)
Increase of CFTR channel function using ONB-CFTR and CFTR modulators (correctors and/or potentiators) under the conditions tested.	The increase will be assessed in comparison to oligonucleotide-control effect by using electrophysiological assays (Ussing chamber).	21 days after the air-liquid switch of epithelia (i.e. full differentiation)

Collaborators and Investigators

• Sponsor: University Hospital, Montpellier
• Collaborators: Hôpital Cochin; Hôpital Necker-Enfants Malades; Foch Hospital, Suresnes, FRANCE

Study record dates

Study Major Dates

• Study Start (Actual): March 30, 2022
• Primary Completion (Estimated): September 30, 2025
• Study Completion (Estimated): September 30, 2027

Study Registration Dates

• First Submitted: September 6, 2021
• First Submitted That Met QC Criteria: October 19, 2021
• First Posted (Actual): October 29, 2021

Study Record Updates

• Last Update Posted (Actual): November 7, 2023
• Last Update Submitted That Met QC Criteria: November 6, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: genetics; cystic fibrosis; personalized therapy; intronic variant; Antisense OligoNucleotide strategy; splicing events
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Respiratory Tract Diseases; Lung Diseases; Infant, Newborn, Diseases; Genetic Diseases, Inborn; Pancreatic Diseases; Fibrosis; Cystic Fibrosis
• Other Study ID Numbers: RECHMPL20_0423; 2020-A03529-30 (Other Identifier: ANSM)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No